June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
Implementation of the Glaucoma Computerized Adaptive Testing System (GlauCAT) to measure the quality of life (QoL) among glaucoma patients in a tertiary eye care setting
Author Affiliations & Notes
  • Ana M Roldan
    Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States
  • Omar Alaa Halawa
    Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States
    Harvard Medical School, Boston, Massachusetts, United States
  • Ryan Sameen Meshkin
    Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States
    Harvard Medical School, Boston, Massachusetts, United States
  • Nazlee Zebardast
    Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States
    Harvard Medical School, Boston, Massachusetts, United States
  • Eva K Fenwick
    Singapore Eye Research Institute, Singapore, Singapore
  • Ecosse Luc Lamoureux
    Duke-NUS Medical School, Singapore, Singapore
    Singapore Eye Research Institute, Singapore, Singapore
  • David S Friedman
    Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States
    Harvard Medical School, Boston, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Ana Roldan, None; Omar Halawa, None; Ryan Meshkin, None; Nazlee Zebardast, None; Eva Fenwick, None; Ecosse Lamoureux, None; David Friedman, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 3514. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ana M Roldan, Omar Alaa Halawa, Ryan Sameen Meshkin, Nazlee Zebardast, Eva K Fenwick, Ecosse Luc Lamoureux, David S Friedman; Implementation of the Glaucoma Computerized Adaptive Testing System (GlauCAT) to measure the quality of life (QoL) among glaucoma patients in a tertiary eye care setting. Invest. Ophthalmol. Vis. Sci. 2021;62(8):3514.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : This study aims to assess: (a) the feasibility of GlauCAT in a busy glaucoma clinic; and (b) the correlation of patients’ responses on five QoL domains with the severity of glaucoma.

Methods : We conducted a cross-sectional study of 138 English-speaking adults aged ≥18 years attending a tertiary eye center glaucoma clinic. Patients with a history of intraocular surgery 90 days before enrollment and/or with cognitive impairment were excluded. GlauCAT, a tablet-based survey, uses item banks and CAT methods to measure the impact of glaucoma and its treatments on five QoL domains listed in Table 1. The domain scores ranged between 1-100, with higher scores representing better QoL outcomes. Feasibility was assessed using a 4-point satisfaction survey and the percentage of patients who completed GlauCAT without assistance. Differences in scores between glaucoma severity groups were assessed using the Kruskal-Wallis test.

Results : 69.6% of patients who completed GlauCAT did so without assistance. The satisfaction survey score had a mean of 3.49±0.53; no statistically significant difference in mean scores was found between the severity groups (p= 0.8). The mobility domain score was higher, with a mean of 93.3±8.6, in the glaucoma suspect group compared to 91.7±11.9 in the early glaucoma group and 79.5±27.1 in the moderate-severe group (p=0.001). The same trend was observed in the concerns domain; the moderate-severe glaucoma group had a significantly lower mean score of 69.8±19.8, followed by the early glaucoma group with 81.1±14.5 and the glaucoma suspects group with a mean of 86.3±8.9 (p=0.001). There was also a significant difference in activity limitation scores by severity group, with higher scores in the glaucoma suspect group (mean 87.0±15.3) than in the moderate-severe glaucoma group (mean 72.8±25.1, p=0.003). The ocular comfort and emotional well-being domains were not statistically significantly different between the three groups of glaucoma severity (p=0.776 and p=0.149, respectively).

Conclusions : Patients with more severe disease reported greater limitations. GlauCAT is a promising tool for assessing and monitoring glaucoma patients’ QoL, as it can be self-administered with high patient satisfaction.

This is a 2021 ARVO Annual Meeting abstract.

 

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×